Edwin P M Jansen
Overview
Explore the profile of Edwin P M Jansen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
1491
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van Schie P, Huisman R, Wiersma T, Knegjens J, Jansen E, Brandsma D, et al.
Neurooncol Adv
. 2025 Mar;
7(1):vdaf027.
PMID: 40051659
Background: Novel systemic therapies, such as immunotherapy and targeted therapies, have shown better systemic disease control in the last decennium. However, the effect of these treatments on distant brain failure...
2.
Caspers I, Slagter A, Lind P, Sikorska K, Wiklund K, Ponten F, et al.
J Surg Oncol
. 2023 Dec;
129(4):734-744.
PMID: 38073160
Background And Objective: This study aims to investigate the impact of sex on outcome measures stratified by histological subtype in patients with resectable gastric cancer (GC). Methods: A post-hoc analysis...
3.
Slagter A, Caspers I, van Grieken N, Walraven I, Lind P, Meershoek-Klein Kranenbarg E, et al.
Cancers (Basel)
. 2022 Jun;
14(12).
PMID: 35740628
(1) Background: Perioperative chemotherapy is the current standard treatment for patients with resectable gastric cancer. Based on studies in patients with metastatic gastric cancer, oxaliplatin has replaced cisplatin in the...
4.
van Amelsfoort R, Walraven I, Kieffer J, Jansen E, Cats A, van Grieken N, et al.
J Natl Compr Canc Netw
. 2022 Mar;
20(3):261-267.
PMID: 35276669
Background: The evaluation of health-related quality of life (HRQoL) in clinical trials has become increasingly important because it addresses the impact of treatment from the patient's perspective. The primary aim...
5.
van Amelsfoort R, van der Sluis K, Schats W, Jansen E, van Sandick J, Verheij M, et al.
Cancers (Basel)
. 2021 Dec;
13(23).
PMID: 34885043
Background: Current treatment strategies have been designed to improve survival in locally advanced gastric cancer patients. Besides its impact on survival, treatment also affects health-related quality of life (HRQOL), but...
6.
Slagter A, Vollebergh M, Caspers I, van Sandick J, Sikorska K, Lind P, et al.
Gastric Cancer
. 2021 Oct;
25(2):401-410.
PMID: 34714423
Aim: To evaluate the prognostic value of tumor markers in a European cohort of patients with resectable gastric cancer. Methods: We performed a post hoc analysis of the CRITICS trial,...
7.
Caspers I, Sikorska K, Slagter A, van Amelsfoort R, Meershoek-Klein Kranenbarg E, van de Velde C, et al.
Cancers (Basel)
. 2021 Sep;
13(18).
PMID: 34572852
Gastric cancer (GC) patients at high risk of developing peritoneal metastasis (PM) as a single site of metastasis after curative treatment may be candidates for adjuvant prophylactic strategies. Here we...
8.
Mendez Romero A, Schillemans W, van Os R, Koppe F, Haasbeek C, Hendriksen E, et al.
Int J Radiat Oncol Biol Phys
. 2021 Jan;
109(5):1377-1386.
PMID: 33451857
Purpose: Although various studies have reported that stereotactic body radiation therapy (SBRT) for liver metastases has high local control rates and relatively low toxicity, most series included a small number...
9.
Slagter A, Vollebergh M, Jansen E, van Sandick J, Cats A, van Grieken N, et al.
Front Oncol
. 2020 Dec;
10:614907.
PMID: 33330111
Gastric cancer is the fifth most common cancer worldwide and has a high mortality rate. In the last decades, treatment strategy has shifted from an exclusive surgical approach to a...
10.
Slagter A, Sikorska K, Grootscholten C, van Laarhoven H, Lind P, Nordsmark M, et al.
Cancer Med
. 2020 Aug;
9(18):6609-6616.
PMID: 32735752
Background: The occurrence of a venous thromboembolism (VTE) is common in patients with cancer. Gastric cancer has been associated with one of the highest risks for VTE. Chemotherapy, especially cisplatin...